H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)
Tweet Send to a Friend
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
